

Specialised Rheumatology (Adult) Quality Dashboard 2016/17

Indicator Reference Number	Domain	Theme	Measure	Rationale	Indicator Name/Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes_1
RHEUM01a	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Timely appointments		Mean time from receipt of initial GP referral to first attended dedicated specialist non urgent OPD appointment for patients with connective tissue disease and/or vasculitis	Total time in days (i.e. total sum of time in days from receipt of new GP referral to first attended appointment)	Total number of new GP referrals for patients with suspected or confirmed connective tissue disease and/or vasculitis seen within the reporting period.	Quarterly	Quarterly	Local Trust	Local Trust		Lower is better	For patients who have postponed own appointment include date from registering referral to first offered appointment
RHEUM01b	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Timely appointments		Mean time from receipt of secondary care referral to first attended dedicated specialist non urgent OPD appointment for patients with connective tissue disease and/or vasculitis	Total time in days (i.e. total sum of time in days from receipt of secondary care referral to first attended appointment)	Total number of secondary care referrals for patients with suspected or confirmed connective tissue disease and/or vasculitis seen within the reporting period.	Quarterly	Quarterly	Local Trust	Local Trust		Lower is better	For patients who have postponed own appointment include date from registering referral to first offered appointment
RHEUM01c	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Timely appointments		Mean time from receipt of initial GP referral to first attended dedicated specialist non urgent OPD for patients with inherited connective tissue diseases and/or metabolic bone	Total time in days i.e. total sum of time in days from receipt of new GP referral to first attended appointment)	Total number of new GP referrals for patients with suspected or confirmed inherited connective tissue diseases and/or metabolic bone seen within the reporting period	Quarterly	Quarterly	Local Trust	Local Trust		Lower is better	For patients who have postponed own appointment include date from registering referral to first offered appointment
RHEUM01d	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Timely appointments		Mean time from receipt of secondary care referral to first attended dedicated specialist non urgent OPD for patients with inherited connective tissue diseases and/or metabolic bone	Total time in days (i.e. total sum of time in days from receipt of secondary care referral to first attended appointment)	Total number of secondary care referrals for patients with suspected or confirmed inherited connective tissue diseases and/or metabolic bone seen within the reporting period.	Quarterly	Quarterly	Local Trust	Local Trust		Lower is better	For patients who have postponed own appointment include date from registering referral to first offered appointment
RHEUM02a	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Day Case specialised service specification activity		Proportion of rheumatology day case treatments that fall within the specialised service specification for the following diagnoses: A) SLE B) Systemic sclerosis C) Myositis D) Vasculitis E) Primary Sjogren's Syndrome F) Osteogenesis imperfecta	From denominator, total number of specialised rheumatology day case treatments with the following diagnoses: A) SLE B) Systemic sclerosis C) Myositis D) Vasculitis E) Primary Sjogren's Syndrome F) Osteogenesis imperfecta	Total number of rheumatology day case treatments performed (within the reporting period)	Quarterly	Quarterly	Local Trust	Local Trust			Numerator note: Number of specialised rheumatology patients with relevant diagnoses using coding for episode.

Specialised Rheumatology (Adult) Quality Dashboard 2016/17

Indicator Reference Number	Domain	Theme	Measure	Rationale	Indicator Name/Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes_1
RHEUM02b	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Inpatient specialised service specification activity		Proportion of rheumatology inpatients admitted that fall within the specialised service specification for the following diagnoses: A) SLE B) Systemic sclerosis C) Myositis D) Vasculitis E) Primary Sjogren's Syndrome F) Osteogenesis imperfecta	From denominator, total number of rheumatology patients admitted with the following diagnoses: A) SLE B) Systemic sclerosis C) Myositis D) Vasculitis E) Primary Sjogren's Syndrome F) Osteogenesis imperfecta	Total number of rheumatology patients admitted (within the reporting period)	Quarterly	Quarterly	Local Trust	Local Trust			Numerator note: Number of specialised rheumatology patients with relevant diagnoses using coding for episode.
RHEUM03	Domain 3: Helping people to recover from episodes of ill health or following injury	Process	Registry registration		Proportion of patients with SLE who received rituximab and are registered on BILAGBR (British Isles Lupus Assessment Group Biologics Registry)	From denominator, total number of patients who received rituximab and are registered on BILAGBR	Number of patients with SLE who received rituximab (within the reporting period)	Quarterly	Quarterly	Local Trust/BILAGBR	Local Trust		Higher is better	Number of patients may not equal number of infusions, as a patient may have received two pulses, as part of a course of rituximab
RHEUM04	Domain 3: Helping people to recover from episodes of ill health or following injury	Process	Registry registration		Proportion of patients with ANCA-associated vasculitis who received rituximab and are registered on UKIVAS	From denominator, total number of patients who received rituximab and are registered on UKIVAS	Number of patients with ANCA-associated vasculitis who received rituximab (within the reporting period)	Quarterly	Quarterly	Local Trust/UKIVAS	Local Trust		Higher is better	Number of patients may not equal number of infusions, as a patient may have received two pulses, as part of a course of rituximab
RHEUM05	Domain 3: Helping people to recover from episodes of ill health or following injury	Process	Registry registration		Proportion of patients with systemic sclerosis who received bosentan for severe digital ulcers and are registered on the DUO registry	From denominator, total number of patients who received bosentan and are registered on the DUO registry	Number of patients with systemic sclerosis who received bosentan for severe digital ulcers (within the reporting period)	Quarterly	Quarterly	Local Trust/DUO registry	Local Trust		Higher is better	
RHEUM06a	Domain 1: Preventing people from dying prematurely	Process	Time to first treatment		Mean time (in days) from decision to give first pulse of cyclophosphamide for priority indication to delivery of treatment on day case unit	Total time (in days) to first pulse of cyclophosphamide (i.e. sum of days for each patient with priority indication)	Number of first pulses of IV cyclophosphamide given (within the reporting period)	Quarterly	Quarterly	Local Trust	Local Trust		Lower is better	Priority indication defined as treatment for severe acute organ-threatening disease e.g. severe vasculitis. Time to first pulse of cyclophosphamide is from the date the treatment slot was requested to the date treatment given.
RHEUM06b	Domain 1: Preventing people from dying prematurely	Process	Time to first treatment		Mean time (in days) from decision to give first pulse of cyclophosphamide for non-priority indication to delivery of treatment on day case unit	Total time (in days) to first pulse of cyclophosphamide (i.e. sum of days for each patient with non priority indication).	Number of first pulses of IV cyclophosphamide given (within the reporting period)	Quarterly	Quarterly	Local Trust	Local Trust		Lower is better	Non priority indication defined as treatment for non acute indication with no imminent organ threatening disease e.g. SSC-ILD. Time to first pulse of cyclophosphamide is from the date the treatment slot was requested to the date treatment given.

Specialised Rheumatology (Adult) Quality Dashboard 2016/17

Indicator Reference Number	Domain	Theme	Measure	Rationale	Indicator Name/Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes_1
RHEUM07a	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical Process	Patient participation in research studies		Proportion of all specialised rheumatology service patients seen in OPD who have participated in National Institute for Health Research (NIHR) Clinical Research Network Portfolio studies (Cross sectional)	From denominator, number of specialised rheumatology service patients who have participated in NIHR-registered cross sectional research studies (within the reporting period)	Number of specialised service rheumatology patients seen in OPD (within the reporting period)	Quarterly	Quarterly	Local Trust	Local Trust			Refers to patients who participate in a research study for one off visits to provide data/samples. A patient may participate in more than one research study and multiple counting is allowed. Data for denominator should be specialised rheumatology patients attending dedicated clinics/MDTs. For the purposes of the quality dashboard, a specialised rheumatology patient is one with a rheumatology diagnosis that is included in the service specification for specialised rheumatology (adult) A13/S/a: 1. Autoimmune connective tissue diseases and vasculitis: e.g. SLE, systemic sclerosis, dermatomyositis, polymyositis, primary Sjogren's syndrome, ANCA associated vasculitis, polyarteritis nodosa, Takayasu's arteritis 2. Inherited connective tissue diseases: e.g. Ehlers Danlos syndrome (excluding type III), Marfan's syndrome, pseudoxanthoma elasticum 3. Complex metabolic bone syndromes: e.g. osteogenesis imperfecta, fibrous dysplasia, chondrodysplasia
RHEUM07b	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical Process	Patient participation in research studies		Proportion of all specialised rheumatology service patients seen in OPD who have participated in National Institute for Health Research (NIHR) Clinical Research Network Portfolio studies - Longitudinal (includes longitudinal observational studies and interventional studies)	From denominator, number of specialised rheumatology service patients who have participated in on-going NIHR-registered longitudinal research studies (within the reporting period)	Number of specialised service rheumatology patients seen in OPD (within the reporting period)	Quarterly	Quarterly	Local Trust	Local Trust			Refers to patients who are participating in a longitudinal study with two or more visits e.g. RCT, etc. A patient may participate in more than one research study and multiple counting is allowed. Data for denominator should be specialised rheumatology patients attending dedicated clinics/MDTs. For the purposes of the quality dashboard, a specialised rheumatology patient is one with a rheumatology diagnosis that is included in the service specification for specialised rheumatology (adult) A13/S/a: 1. Autoimmune connective tissue diseases and vasculitis: e.g. SLE, systemic sclerosis, dermatomyositis, polymyositis, primary Sjogren's syndrome, ANCA associated vasculitis, polyarteritis nodosa, Takayasu's arteritis 2. Inherited connective tissue diseases: e.g. Ehlers Danlos syndrome (excluding type III), Marfan's syndrome, pseudoxanthoma elasticum 3. Complex metabolic bone syndromes: e.g. osteogenesis imperfecta, fibrous dysplasia, chondrodysplasia

Data collection has been approved by the Review of Central Returns - ROCR  
ROCR/OR/2230/001MAND